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Objective - A process of melt granulation whereby the drug powder is mixed with a melted wax has 
been used to modify the dissolution rates of drug particles. The present study investigated how the 
incorporation of hydrophobic materials (talc or magnesium stearate) in the core of such granules may 
further retard drug release.  
Method - The hydrophobic powder was mixed with the drug (paracetamol) powder prior to melt 
granulation with Carnuba wax. Content of the hydrophobic material varied from 0 to 50% but the content 
of wax was constant. Conventional granules of paracetamol were formed by wet massing the 
paracetamol powder with starch mucilage 20%w/v, followed by screening and drying. The granules were 
subjected to dissolution test.  
Results - The results indicated that melt granulation remarkably retarded the dissolution rates of 
paracetamol granules. The rates can be further retarded by inclusion of an internal hydrophobic 
material. The dissolution rate of the conventional granules was 32%h-1 as against 11.6%h-1 (melt 
granules) and 10.3%h-1 (melt granules with intragranular hydrophobic agents, 5%w/w). 
Conclusion - The indication is that the inclusion of an intragranular hydrophobic agent in the melt 
granules can be used to obtain further control of drug release 
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INTRODUCTION 
Controlled release solid dosage forms are 
available either as single unit or as multiple unit 
forms1, 2. A multiunit dosage form thus consists 
of particles (units) of differing release profiles 
with respect to onset, rate and the maximum 
release, etc. Controlled-release products are 
designed to decrease the dosing frequency and 
enhance patient compliance. In the last two 
decades, sustained - release dosage forms have 
made significant progress in terms of clinical 
efficacy and patient compliance3.  
Preparation of drug - embedded matrix tablets 
that involves the direct compression of a blend of 
drug and the matrix forming additives is one of 
the least complicated approaches for delivering 
drug in a controlled release pattern into the 
systemic circulation4. In an alternative approach, 
a combination of talc and magnesium stearate 
has been used to achieve zero -order release of 
ibuprofen from extended release tablets5. Talc is 
mainly used as a glidant and magnesium 
stearate as a lubricant in tablet formulations. 
Both materials are hydrophobic with a potential 
to repel water influx into tablets, hence retard 
drug release from such tablets. Previous 
studies6, 7 have also shown that melt granulation 
(whereby the drug powder is triturated with a 
melted wax to form granules) is an effective 
means of retarding drug from drug particles. 
More recently, this technique has been used to 
retard the release of paracetamol from its melt 
granules using goat wax, carnuba wax and 
glyceryl monosterate in the melt granulation8.  
The purpose of the present study is to 
investigate how incorporation of hydrophobic 
agents (talc and magnesium stearate) will further 
modify the release profiles of the melt granules. 
The study thus sought for a simple approach for 
effectively modifying drug release from granules. 
Such granules could ultimately be encapsulated 
or tableted for multi-unit dose applications. 
 
MATERIALS AND METHODS 
Materials 
Carnuba wax (Halewood Chemicals Ltd, 
England) was used in the melt granulation. It is a 
fine waxy solid with melting point of 82-880C, 
yellowish in colour. It was selected as material 
for coating because it is not sticky; hence it 
produces free flowing granules compared with 
other wax materials (i.e., goat fat and glyceryl 
monosterate). Talc (Get-Rid Pharm Pvt, Ltd, 
Pune, India) and magnesium stearate (BDH, 
Poole, UK). The test drug, paracetamol, was 
supplied by BDH (Poole, UK). Although 
sustained release formulations are usually 
applied to potent drugs with short biologic half - 
life, a readily available drug (paracetamol) was 
used to demonstrate the principle of retard 
release by melt granulation. 
 
Methods 
Melt granulation technique 
Carnuba wax (20g) was melted in a stainless 
steel container in a water bath at a temperature 
higher than the melting point of the wax material 
(i.e., 900C). Paracetamol and the hydrophobic 
material (i.e., talc or magnesium stearate 
powder) were blended in varying proportions 
(Table 1). A sample of the paracetamol alone or 
the powder mixture (80g) was mixed with the 
melted wax in a Kenwood mixer (Model A901P 
England). The mass was pressed through a 
sieve of 710µm aperture size and dried in a 
vacuum oven (model A2904, Gallenkamp, 
England) at 250C for 1h. Convectional granules 
of paracetamol were produced by wet massing a 
sample of the paracetamol powder (100g) with 
20%w/v starch mucilage (38ml). The wet mass 
was screened and dried in a vacuum oven at 
250C for 1h. Moisture content of the resulting 
granules were 2.3±1.1%w/w (conventional 
granulation) and 2.1±1.5%w/w (melt 
granulation). 
Dissolution test 
Fines of size (< 210µm) were removed from the 
granules by sieving. A sample of the granules 
(500mg) was filled into a capsule shell and 
placed in a cylindrical basket (aperture size 
425µm, diameter 20mm; height 30mm), which 
was immersed in 800ml of leaching fluid (0.1N 
hydrochloric acid maintained at 37 ± 2oC). The 
fluid was stirred at 100rpm with a single blade 
GallenKamp stirrer (Model APP No 4B 5784A. 
Cat No: SS530). Samples (5ml) were withdrawn 
from the leaching fluid at selected time intervals 
with a pipette fitted with a cotton wool plug, 
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replacing with an equal volume of drug-free 
dissolution fluid. The samples were suitably 
diluted with blank dissolution fluid and analysed 
for content of paracetamol 
spectrophotometrically at λ max, 245nm using 
Spectronic 21D, (Bausch and Lomb, USA). For 
the wax-coated granules, the samples were kept 
in the fridge overnight to allow solidification of 
the melted wax, which may have leached during 
the dissolution test. The samples were filtered 
before assay. The amounts released were 
expressed as a percentage of the initial amount 
of drug in the granule samples. The 
determination was carried out in triplicate and 
the mean results reported. Plots of amounts 
released (%) vs time were constructed. The 
release rates were obtained from the slopes of 
the linear portions of the plots. Other parameters 
obtained from the plots were the maximum 
release (m∞) and the time to attain it (t∞). 
 
RESULTS  
Effect of melt granulation on the release profiles 
of the drug particles 
The effect of melt granulation on the release 
profiles of paracetamol is shown in Fig 1. The 
melt granulations displayed a retarded release 
compared with the conventional granules. For 
instance, with the convectional granules, 
maximal release was achieved in 3h and the 
dissolution rate was 32.3%h-1. After melt 
granulation with the carnuba wax, maximal 
release was now achieved in 8h, with a 
dissolution rate of 11.6%h-1.  
 
 
Table 1: Composition of the melt granules with varying content of hydrophobic agent (talc or magnesium 





powder (g)   
% hydrophobic agent in the 
powder mixture 
0 80 0 
4 76 5 
8 72 10 
16 64 20 
24 56 30 
32 48 40 
40 40 50 









m∞ (%) t∞  (h)  Release rate %h
-1 
 Talc Magnesium  
stearate 
Talc Magnesium  
stearate 
Talc Magnesium  
Stearate 
0 93 93 8 8 11.6 11.6 
5 93 92 9 9 10.3 10.2 
10 92 92 9 9 10.2 10.2 
20 92 92 9 9 10.2 10.2 
30 92 91 9 10 10.2 9.1 
40 91 90 10 10 9.1 9 
50 90 90 10 10 9 9 
Note: 0% means no hydrophobic agent was added. 
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Fig 2: Effect of incorporation of a hydrophobic agent (HA) on drug release profile of the melt granules. 
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Effect of incorporation of hydrophobic agents on 
the drug release profiles of the melt granules. 
The results on the effect of incorporation of 
hydrophobic agents (i.e., talc or magnesium 
stearate) on the drug release profiles of the melt 
granulations are presented in Fig 2. The results 
showed that the release rates of the melt 
granulations were further retarded following the 
incorporation of a hydrophobic agent (i.e., talc or 
magnesium stearate) particularly when the talc 
or magnesium stearate content of the granules 
was ≥ 30%w/w. For instance, with the melted 
granules only (no hydrophobic agent), maximal 
drug release was achieved in 8h. When 
hydrophobic agents were incorporated in the 
granules (30%w/w), maximal release was now 
achieved in 10h. In other words, maximum 
release was prolonged by a further 2h. However, 
increase in the hydrophobic agent content 
beyond 30%w/w did not retard the extent of drug 
release further (Table 2). Hence, 30%w/w was 
considered as the optimal concentration of the 
hydrophobic agent to be used in the formulation 
of the retard release granules. The release data 
in Table 2 also showed that talc and magnesium 
stearate were equivalent in retarding drug 
release from the granules.  
 
DISCUSSION 
Regression analysis of the dissolution data on 
the basis of zero order, first order and Higuchi 
square root of time kinetics revealed that drug 
release from the melt granulations was generally 
consistent with the Higuchi kinetics (R2 ≥ 98). On 
the other hand, R2 values for the conventional 
granules were generally low but increased to ≥ 
95 when the data were plotted on the basis of an 
initial zero order (first 55% release) followed by a 
first order profile for the remaining 45%. The 
zero/ first order profile for the conventional 
granules indicates a dissolution (erosion) 
mechanism8, while the Higuchi kinetic for the 
melt granulations indicates a diffusion controlled 
mechanism9. Therefore, the melt granules are 
more adaptable for prolonged release 
applications. The further retardation of drug 
release by the hydrophobic agents is attributable 
to the water repellant property of such agents. 
 
CONCLUSION  
The study showed that drug release from melt 
granulations could be effectively modified by 
intragranular incorporation of hydrophobic 
excipients (talc or magnesium stearate) to 
achieve retard drug release. The approach thus 
provides a means of further controlling drug 
release from the melt granulations. This finding 
can be exploited in the design of multi-unit 
dosage forms which provide a prompt release 
(from conventional granules) followed by a 
sustained release (from the melt granulations), 
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